Oral administration of Lactococcus lactis subsp. lactis JCM5805 enhances lung immune response resulting in protection from murine parainfluenza virus infection.
When activated by viral infection, plasmacytoid dendritic cells (pDCs) play a primary role in the immune response through secretion of IFN-α. Lactococcus lactis subsp. lactis JCM5805 (JCM5805) is a strain of lactic acid bacteria (LAB) that activates murine and human pDCs to express type I and type III interferons (IFNs). JCM5805 has also been shown to activate pDCs via a Toll-like receptor 9 (TLR9) dependent pathway. In this study, we investigated the anti-viral effects of oral administration of JCM5805 using a mouse model of murine parainfluenza virus (mPIV1) infection. JCM5805-fed mice showed a drastic improvement in survival rate, prevention of weight loss, and reduction in lung histopathology scores compared to control mice. We further examined the mechanism of anti-viral effects elicited by JCM5805 administration using naive mice. Microscopic observations showed that JCM5805 was incorporated into CD11c+ immune cells in Peyer's patches (PP) and PP pDCs were significantly activated and the expression levels of IFNs were significantly increased. Interestingly, nevertheless resident pDCs at lung were not activated and expressions levels of IFNs at whole lung tissue were not influenced, the expressions of anti-viral factors induced by IFNs, such as Isg15, Oasl2, and Viperin, at lung were up-regulated in JCM5805-fed mice compared to control mice. Therefore expressed IFNs from intestine might be delivered to lung and IFN stimulated genes might be induced. Furthermore, elevated expressions of type I IFNs from lung lymphocytes were observed in response to mPIV1 ex vivo stimulation in JCM5805-fed mice compared to control. This might be due to increased ratio of pDCs located in lung were significantly increased in JCM5805 group. Taken together, a specific LAB strain might be able to affect anti-viral immunological profile in lung via activation of intestinal pDC leading to enhanced anti-viral phenotype in vivo.
Technical Deveropment Center, Koiwai Dairy Products Co Ltd. Sayama, Japan; Central Laboratories for Key Technologies, Kirin Co. Ltd., Yokohama, Japan.
Kenta
K
Jounai
Central Laboratories for Key Technologies, Kirin Co. Ltd., Yokohama, Japan.
Tetsu
T
Sugimura
Central Laboratories for Key Technologies, Kirin Co. Ltd., Yokohama, Japan.
Konomi
K
Ohshio
Central Laboratories for Key Technologies, Kirin Co. Ltd., Yokohama, Japan.
Daisuke
D
Fujiwara
D000284:Administration, Oral; D000818:Animals; D005260:Female; D013294:Lactococcus lactis; D008168:Lung / Q000276:immunology*; D051379:Mice; D008811:Mice, Inbred DBA; D018184:Paramyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*